"If you're a medical doctor I don't suppose you can tell us why they are trying to hide the note conversion notice in the option conversion notice."
Question 2.)
"But you may be able to tell us about a rival company that is doing viriolog and has been hugely successful. Can you?"
Answer 1.)
This is strictly my opinion!!! I have absolutely no internal knowledge of this company!!! IMO, I think it was a form of avoidance behaviour! I believe that in the middle of the global financial crisis, VLA has a few problems, not in the laboratory, but with funding. The business is basically "back-to-front". Like all biotech companies, it spends money and will only get an income, if at all, at the end of the process!!! La Jolla Cove arrived at the critical moment and a deal was struck up. I don't think VLA's management, for a moment, felt that La Jolla Cove would be as ruthless as they were in the last 4 weeks with their dumping of about 23 million shares, they exchanged in repayment for loans. So the VLA amangement, being a little embarrassed about what happened (which was out of their control in any case!) they chose to convey the information in a slightly "concealed" fashion. Nothing was left out, but you had to hunt for the "meat" of the announcement!!!
PS: You don't have to be a doctor to derive this opinion, but the psychological motivation underlying the behaviour, I guess is slight tricky to analyse!!!
Answer 2.)
Look Gav, I know you are a sceptic, but it all happening around you??! This will all come about!!! and when it does you will regret you oppose my sentiments!!!
It's easly...relax....feel your body becoming heavy...your eyes are tired and you want to drift off into the most relaxing sleep, away from all the problems of life....When I click my fingers you will enter a deep sleep...but you will still be able to hear my voice and obey my every command!....."You will suddenly feel an intense enthusiasm for the concept of Oncolytic Viral Therapy....you will believe in the technology implicitly....you will feel like a heavy burden has been lifted from your shoulders ...and you will feel totally relaxed and at peace with yourself and the world....you will have an overpowering insight into the interconnection of life and the universe and you will experience a powerfully focused and intensely satisfying understanding of the "meaning of life" and the role you personal will play in the history of mankind!!!....I click my fingers again, you will continue to obey my instructions in the future....but you will wake up refreshed, with no memory this occurance!!!"
Okay here is some of the lastest stuff!!!
Oncolytic virus therapy for prostate cancer Authors: Fukuhara, Hiroshi; Homma, Yukio1; Todo, Tomoki Source: International Journal of Urology, Volume 17, Number 1, January 2010 , pp. 20-30(11) Publisher: Blackwell Publishing
Abstract: The use of replication-competent viruses that can selectively replicate in and destroy neoplastic cells is an attractive strategy for treating cancer. Various oncolytic viruses have been taken to clinical trials since a recombinant virus was first applied to cancer patients a decade ago. The concept of the therapy is simple: infectious virus kills the host cancer cells in the course of viral replication. It is important, however, that the virus does not harm the surrounding normal tissue. Oncolytic viruses can be classified largely into two groups: DNA viruses genetically engineered to achieve cancer specificity (e.g. adenovirus, herpes simplex virus and vaccinia) and RNA viruses of which human is not the natural host (e.g. Newcastle disease virus and reovirus). Prostate cancer has always been one of the major targets of oncolytic virus therapy development. The result of six clinical trials for prostate cancer has been published and several trials are now going on. Forty-eight of 83 (58%) patients evaluated in the phase I studies demonstrated a >25% decrease in serum prostate-specific antigen level without evidence of severe toxicities. The result shows the oncolytic virus therapy is promising toward clinical application. Here, we review the recent advances in the field and summarize the results from clinical trials.
New Viral Therapy Against Cancer It addresses many types of tumors By Tudor Vieru, Scientific Editor. 11th February 2010.
Scientists at Oncolytics Biotech Inc., a Calgary, Canada-based company, announce that they are in the final stages of developing a new type of viral therapy against many forms of cancerous cells. They add that the method relies on using a certain type of usually harmless virus against tumors, which is able to morph into a very powerful killing machine, capable of selecting against healthy cells. In the technique developed at OB, the common viral agent turns deadly within three days, and the experts are in the final stages of testing the therapy, before the research is concluded.
Acording to documents we received from the company, the new form of therapy, Reolysin, addresses a broad range of cancers, from that affecting the head and neck to the ones destroying lungs and livers. It would appear that the new form of treatment produces only minor side-effects in patients, while also remaining highly effectivce in killing the infected cells. This means that, if the product turns out to be working properly in the end, we could witness a complete reshaping of the way several types of cancers are now being handled.
The reovirus (Respiratory Enteric Orphan virus) is the main target of investigation here. Specialists at OB say that the agent causes little to no health problems in humans, and that most people's immune systems learn how to deal with it by the age of 12. However, cancer cells have yet to develop a way of handling it, so, if the microorganism is injected into tumors, the cells within die within three days of contact. This approach has proven successful on so many cancers, that the scientific and medical communities are buzzing with excitement.
Reolysin works well in combination with the typical first line and second line chemotherapeutic products, the CEO of Oncolytics Biotech, Dr. Brad Thompson, explains. He reveals that clinical trials using both the viral agent and chemotherapy or radiation have proven to be extremely effective at promoting cancer-cell death. But the difference between these therapies occurs in the side-effects they produce. While chemo and radiation produce significant shifts in a patient's quality of life, Reolysin only triggers minor, flu-like symptoms. Thomson says that the low-grade fever and the tiredness associated with this therapy pass within 24 to 48 hours.
Oncolytics is the first company to reach an agreement with the FDA on a Phase 3 trial design for an intravenously-administered oncolytic virus under the SPA process. This is an exciting step forward for our clinical program for REOLYSIN, which has become a first-in-class agent, Dr. Thompson concludes.
